Amiodarone-induced Thyrotoxicosis with Cardiopulmonary Arrest

Kosuke Inoue¹, Jun Saito¹, Tetsuo Kondo², Kaoru Miki³, Chiho Sugisawa¹, Yuya Tsurutani¹, Naoki Hasegawa¹, Shinya Kowase³, Yukio Kakuta¹, Masao Omura¹ and Tetsuo Nishikawa¹

Abstract:
We describe a case of amiodarone-induced thyrotoxicosis (AIT) with cardiopulmonary arrest (CPA) in a 49-year-old woman. The patient had been treated with amiodarone for non-sustained ventricular tachycardia. Two weeks prior to her admission, she developed thyrotoxicosis and prednisolone (PSL, 30 mg daily) was administered with the continuation of amiodarone. However, she was admitted to our hospital for CPA. We performed total thyroidectomy to control her thyrotoxicosis and the pathological findings were consistent with type 2 AIT. She gradually improved and was discharged on day 84. This case demonstrates the importance of considering immediate total thyroidectomy for patients with uncontrollable AIT.

Key words: Amiodarone-induced thyrotoxicosis, Hyperthyroxinemia, Cardiopulmonary arrest, Prednisolone, Thyroidectomy

(Intern Med Advance Publication)
(DOI: 10.2169/internalmedicine.9177-17)

Introduction

Amiodarone, a widely used antiarrhythmic drug, is known to cause thyroid dysfunction, such as amiodarone-induced thyrotoxicosis (AIT) and amiodarone-induced hypothyroidism (AIH) through its pharmacological and toxic actions (1, 2). AIT represents a diagnostic and therapeutic challenge, while AIH does not cause critical problems in most cases. AIT is classified as type 1 (iodine-induced hyperthyroidism), type 2 (destructive thyroiditis), and mixed type (types 1 and 2) (3). In Japan, where the iodine intake is sufficient, almost all cases of AIT are type 2 and are mainly treated with prednisolone (PSL) (4). However, some cases of type 2 AIT are reported to be resistant to oral PSL therapy (5, 6). Moreover, patients who are treated with amiodarone usually have severe cardiac abnormalities and amiodarone withdrawal is often difficult. In such cases, immediate total thyroidectomy should be considered as a second-line therapy (3) because prolonged thyrotoxicosis has the potential to cause cardiac damage and muscle weakness (7). We herein report a case of uncontrolled type 2 AIT with cardiopulmonary arrest (CPA) which ultimately required total thyroidectomy.

Case Report

A 49-year-old woman was referred to our hospital for thyrotoxicosis. Her significant medical history included severe hypertrophic cardiomyopathy and non-sustained ventricular tachycardia (NSVT). She had been treated with amiodarone (100 mg per day) and an implantable cardioverter-defibrillator (ICD) for 2 years prior to her presentation. She had no personal or family history of thyroid disease. After the initiation of amiodarone treatment, her free thyroxine (FT4), free triiodothyronine (FT3) and thyroid-stimulating hormone (TSH) levels were measured at 3-month intervals. The levels remained normal for the first 2 years of the therapy; however, her most recent test showed hyperthyroxinemia with elevated FT4 (>7.8 ng/dL) and FT3...
Table. Laboratory Findings.

<table>
<thead>
<tr>
<th>Blood samples</th>
<th>Thyroid function</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC 1.93×10⁸/μL</td>
<td>TSH &lt;0.005 μIU/mL</td>
</tr>
<tr>
<td>Hb 12.7 g/dL</td>
<td>Free T4 &gt;7.8 ng/dL</td>
</tr>
<tr>
<td>Plt 28.4×10⁴/μL</td>
<td>Free T3 19.2 pg/mL</td>
</tr>
<tr>
<td>AST 141 IU/L</td>
<td>Tygoglobulin 173.4 ng/mL</td>
</tr>
<tr>
<td>ALT 97 IU/L</td>
<td>TRAb (3rd) &lt;0.4 IU/L</td>
</tr>
<tr>
<td>ALP 435 IU/L</td>
<td>TPOAb &lt;0.3 IU/L</td>
</tr>
<tr>
<td>LDH 326 IU/L</td>
<td>TgAb 1.6 IU/L</td>
</tr>
<tr>
<td>CK 55 IU/L</td>
<td></td>
</tr>
<tr>
<td>BUN 46.3 mg/dL</td>
<td></td>
</tr>
<tr>
<td>Cr 0.68 mg/dL</td>
<td></td>
</tr>
</tbody>
</table>


(19.2 pg/mL) levels, suppressed TSH levels (<0.005 μIU/mL), and undetectable autoimmune thyroid antibody levels, including anti-thyroglobulin, anti-thyrophosphatidase, and anti-TSH receptor antibodies. She complained of a 3-month history of increasing fatigue, loss of appetite, and 7 kg of unintentional weight loss. Type 2 AIT was highly suspected based on her clinical course and the laboratory findings. Amiodarone was continued because her NSVT was difficult to manage with other antiarrhythmic agents. The administration of PSL (30 mg per day, orally [0.5 mg/kg]) was therefore initiated with the continuation of amiodarone. However, 2 weeks later, she was admitted to the intensive care unit of our hospital because of an episode of CPA.

On admission, her height and body weight were 165 cm and 40 kg, respectively. Her Glasgow Coma Scale (GCS) was E1V1M1, her systolic blood pressure was 80 mmHg, and her pulse rate was 100 beats/min. She had a small firm grade 2 goiter (WHO classification). Her ICD recording showed ventricular fibrillation (VF), which was treated by direct current cardioversion (35 J). Table shows the results of the laboratory tests. She had severe thyrotoxicosis, despite the PSL treatment. Her potassium level was 3.6 mEq/L and her amiodarone concentration was 134.1 ng/mL. Moreover, the patient had a high carbon dioxide level (139 mmHg), diaphragmatic paralysis, and respiratory muscle weakness, which required mechanical ventilation. Echocardiography showed diffuse hypokinesis (estimated ejection fraction, 40%) and no asynergy. A thyroid ultrasound showed diffuse goiter (thyroid volume calculated by the ellipsoid formula (8), 43.5 cm³) and color flow Doppler sonography (CFDS) revealed a lack of intraparenchymal vascularity (Fig. 1).

Other reasons for thyrotoxicosis, such as subacute thyrotoxicosis, toxic multinodular goiter, were less likely than AIT because she had used amiodarone for 2 years, and because she had no signs of inflammation (Table), and no signs of nodules in her thyroid (Fig. 1). In addition to the regional characteristics of iodine deficiency in Japan, her autoimmune thyroid antibody negativity and the CFDS findings strengthened the possibility of type 2 rather than type 1 AIT.

Although the PSL dose was increased to 60 mg (1.0 mg/kg) daily, she remained unconscious and her thyroid function tests continued to show hyperthyroxinemia (FT4 >7.8 ng/dL, FT3 >32.6 pg/mL, and TSH < 0.005 μIU/mL). Thus, total thyroidectomy was performed on day 7 after admission. Histologically, most of the thyroid follicles were filled with colloid and lined with flattened follicular epithelial cells. We occasionally found atrophic follicles with fibrosis (Fig. 2a, 2b) and disrupted follicles with the infiltration of macrophages (Fig. 2c). Cytoplasmic vacuolization, deposits of lipofuscin, and the detachment of follicular epithelial cells were observed in these damaged follicles (Fig. 2d). The lymphocytic infiltration was slight. After total thyroidectomy, her thyroid hormone levels gradually decreased. The PSL dose was tapered and levothyroxine was initiated to maintain a euthyroid status on day 12 after admission. Amiodarone (50 mg daily) was continued to control her NSVT. Her unconsciousness, diaphragmatic paralysis, and respiratory muscle weakness gradually improved and she was removed from the mechanical ventilator on day 14. Following rehabilitation, the patient was finally discharged on the 84th day after admission. Treatment with levothyroxine was continued at a dose of 125 μg. Her clinical course is shown in Fig. 3.

Discussion

Amiodarone is a benzofuranic iodine-rich antiarrhythmic drug (class III) that causes thyroid dysfunction in 15-20% of patients (3). Amiodarone contains 75 mg iodine in each 200 mg tablet and releases approximately 10% of the iodine as free iodine each day (1, 9), which affects the thyroid hormone metabolism. The prevalence of AIT is 2% and 12% in iodine-sufficient and iodine-deficient areas, respectively (10). It can also develop after the withdrawal of amiodarone because the drug has a long half-life of approximately 100
Figure 1. Thyroid ultrasound. Right lobe, 2.2 (wide) ×2.7 (depth) ×7.5 (length) cm; left lobe, 2.1×2.4×7.4 cm; Isthmus, 0.36×3.1 cm. The thyroid volume, as calculated by the ellipsoid formula, was 43.5 cm³. Color flow Doppler sonography revealed no intraparenchymal vascularity.

Figure 2. The pathological findings of the thyroid. Atrophic follicles with interstitial fibrosis [a and b: Hematoxylin and Eosin (H&E) staining]. Disrupted follicles with detachment of the follicular epithelium and the macrophage infiltration (c: H&E staining). Cytoplasmic vacuolization and lipofuscin in flattened follicular epithelial cells (d: H&E staining).

days (2). The immediate detection and treatment of AIT are necessary because prolonged thyrotoxicosis causes dangerous and critical situations for patients with cardiac abnormalities.
AIT has two different subtypes: type 1 (a form of iodine-induced hyperthyroidism) and type 2 (a drug-induced destructive thyroiditis) (3). It is important to clarify these two types because they require different therapeutic approaches; antithyroid drugs for type 1 and PSL for type 2 (11). We diagnosed the present case as having type 2 AIT based on the following characteristics: 1) she did not have underlying thyroid disease and was negative for thyroid antibodies; 2) CFDS showed the absence of hypervascularity; and 3) she was living in Japan, where the iodine intake is sufficient and almost all reported AIT cases are type 2 (3). The long duration of amiodarone intake and the increased FT4/FT3 ratio almost all reported AIT cases are type 2 (3). It is important to clarify these two types because they require different therapeutic approaches; antithyroid drugs for type 1 and PSL for type 2 (11).

In conclusion, we experienced a rare case of type 2 AIT in a Japanese patient with CPA who was completely cured after total thyroidectomy. This case demonstrated the importance of detecting thyroid abnormalities in patients with a history of amiodarone use and of treating them as soon as possible because prolonged thyrotoxicosis might cause CPA. Total thyroidectomy should be considered when patients require the immediate restoration of euthyroidism because of severe conditions.

The authors state that they have no Conflict of Interest (COI).
References


The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).